Skip to main content
Erschienen in: International Journal of Colorectal Disease 4/2019

22.01.2019 | Original Article

Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis

verfasst von: Giuseppe Antonio Colloca, Antonella Venturino, Domenico Guarneri

Erschienen in: International Journal of Colorectal Disease | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The introduction of new drugs and multimodal treatments for the management of patients with metastatic colorectal cancer (mCRC) has reduced the importance of time-to-event endpoints and reported the attention on the response-related endpoints. Furthermore, the prognostic role of the surgical scores before the resection of metastases has not been confirmed for multimodal treatments. The purpose of this research is to perform a meta-analysis of the studies that evaluated the relationship between carcinoembryonic antigen (CEA) response and outcome in patients with mCRC receiving systemic chemotherapy.

Methods

A systematic review of the literature on two databases and a selection of studies that evaluated the relationship between CEA response and outcome were performed according to predefined criteria. After, three meta-analyses were carried out on the selected studies, each for each outcome variable.

Results

Nineteen studies have been selected. Fourteen studies (1475 patients) have documented a close association between radiological response and CEA response (odds ratio (OR), 9.03; confidence intervals (CIs), 5.14–15.87; I2 statistic (I2), 72%). Four studies have reported a longer progression-free survival for patients with a CEA response (hazard ratio (HR), 0.73; CIs, 0.64–0.83; I2, 23%). Finally, 10 studies (13 study cohorts) have shown a strong relationship between CEA response and overall survival (OS) (HR, 0. 62; CIs, 0.55–0.70; I2, 35%).

Conclusions

CEA response merits further investigation as a surrogate endpoint of clinical trials of first-line medical therapy of patients with mCRC, and should be studied as a prognostic factor for those patients who are candidates for multimodal treatment strategies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E (2017) European cancer mortality prediction for the year 2017, with focus on lung cancer. Ann Oncol 28:1117–1123CrossRefPubMed Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E (2017) European cancer mortality prediction for the year 2017, with focus on lung cancer. Ann Oncol 28:1117–1123CrossRefPubMed
2.
Zurück zum Zitat Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580CrossRefPubMed Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580CrossRefPubMed
3.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215CrossRefPubMed Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215CrossRefPubMed
4.
Zurück zum Zitat Schreckenbach T, Malkomes P, Bechstein WO, Woeste G, Schnitzbauer AA, Ulrich F (2015) The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastases. Surg Today 45:1527–1534CrossRefPubMed Schreckenbach T, Malkomes P, Bechstein WO, Woeste G, Schnitzbauer AA, Ulrich F (2015) The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastases. Surg Today 45:1527–1534CrossRefPubMed
5.
Zurück zum Zitat Colloca G, Venturino A, Guarneri D (2016) Analysis of clinical end points of randomised trials including bevacizumab and chemotherapy versus chemotherapy as first-line treatment of metastatic colorectal cancer. Clin Oncol 28:e155–e164CrossRef Colloca G, Venturino A, Guarneri D (2016) Analysis of clinical end points of randomised trials including bevacizumab and chemotherapy versus chemotherapy as first-line treatment of metastatic colorectal cancer. Clin Oncol 28:e155–e164CrossRef
6.
Zurück zum Zitat Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S (2013) Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 31:3764–3775CrossRefPubMed Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S (2013) Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 31:3764–3775CrossRefPubMed
7.
Zurück zum Zitat Hammarstrom S (1999) The carcynoembrionic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67–81CrossRefPubMed Hammarstrom S (1999) The carcynoembrionic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67–81CrossRefPubMed
8.
Zurück zum Zitat Tabuchi Y, Deguchi H, Imanishi K, Saitoh Y (1987) Comparison of carcynoembrionic antigen levels between portal and peripheral blood in patients with cororectal cancer. Cancer 59:1283–1288CrossRefPubMed Tabuchi Y, Deguchi H, Imanishi K, Saitoh Y (1987) Comparison of carcynoembrionic antigen levels between portal and peripheral blood in patients with cororectal cancer. Cancer 59:1283–1288CrossRefPubMed
9.
Zurück zum Zitat Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, Hughes TA (2013) Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Brit J Cancer 108:662–667CrossRefPubMedPubMedCentral Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, Hughes TA (2013) Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Brit J Cancer 108:662–667CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedPubMedCentral Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Mayer RJ, Garnick MB, Steele GD, Zamcheck N (1978) Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 42:1428–1433CrossRefPubMed Mayer RJ, Garnick MB, Steele GD, Zamcheck N (1978) Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 42:1428–1433CrossRefPubMed
12.
Zurück zum Zitat Shani A, O’Connell MJ, Moertel CG, Schutt AJ, Silvers A, Go VLW (1978) Serial plasma carcynoembrionic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 88:627–630CrossRefPubMed Shani A, O’Connell MJ, Moertel CG, Schutt AJ, Silvers A, Go VLW (1978) Serial plasma carcynoembrionic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 88:627–630CrossRefPubMed
13.
Zurück zum Zitat Al-Sarraf M, Baker L, Talley RW, Kithier K, Vaitkevicius VK (1979) The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer 44:1222–1225CrossRefPubMed Al-Sarraf M, Baker L, Talley RW, Kithier K, Vaitkevicius VK (1979) The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer 44:1222–1225CrossRefPubMed
14.
Zurück zum Zitat Allen-Mersch TG, Kemeny N, Niedzwiecki D, Shurgot B, Daly JM (1987) Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28:1625–1629CrossRef Allen-Mersch TG, Kemeny N, Niedzwiecki D, Shurgot B, Daly JM (1987) Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28:1625–1629CrossRef
15.
Zurück zum Zitat De Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, Grange JD, Gonzalez-Canali G, Demuynck B, Louvet C, Seroka J, Dray C, Debray J (1988) High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24:1499–1503CrossRefPubMed De Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, Grange JD, Gonzalez-Canali G, Demuynck B, Louvet C, Seroka J, Dray C, Debray J (1988) High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24:1499–1503CrossRefPubMed
16.
Zurück zum Zitat Hamm CM, Cripps C (1998) Carcinoembryonic antigen in metastatic colorectal cancer. Clin Invest Med 21:186–191PubMed Hamm CM, Cripps C (1998) Carcinoembryonic antigen in metastatic colorectal cancer. Clin Invest Med 21:186–191PubMed
17.
Zurück zum Zitat Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786–795CrossRefPubMed Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786–795CrossRefPubMed
18.
Zurück zum Zitat Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Fan FS, Yen CC, Chen WS, Jiang JK, Yang SH (2001) Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer. Int J Color Dis 16:96–101CrossRef Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Fan FS, Yen CC, Chen WS, Jiang JK, Yang SH (2001) Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer. Int J Color Dis 16:96–101CrossRef
19.
Zurück zum Zitat Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B (2002) Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 13:1430–1437CrossRefPubMed Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B (2002) Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 13:1430–1437CrossRefPubMed
20.
Zurück zum Zitat Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chen PM (2002) Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer. Hepatogastroenterol 49:388–392 Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chen PM (2002) Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer. Hepatogastroenterol 49:388–392
21.
Zurück zum Zitat Trillet-Lenoir V, Chapuis F, Touzet S, Barbier JY, Freyer G, Gaudin JL, Lombard-Bohas C, Valette PJ, Lledo G, Gouttebel MC, Boyer JD, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glehen O, Darnand P, Heilmann MO, Bleuse JP (2004) Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol 16:196–203CrossRef Trillet-Lenoir V, Chapuis F, Touzet S, Barbier JY, Freyer G, Gaudin JL, Lombard-Bohas C, Valette PJ, Lledo G, Gouttebel MC, Boyer JD, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glehen O, Darnand P, Heilmann MO, Bleuse JP (2004) Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol 16:196–203CrossRef
22.
Zurück zum Zitat de Haas RJ, Wicherts DA, Flores E, Ducreux M, Levi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R (2010) Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 17:1010–1023CrossRefPubMedPubMedCentral de Haas RJ, Wicherts DA, Flores E, Ducreux M, Levi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R (2010) Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 17:1010–1023CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S (2012) Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Investig New Drugs 30:758–764CrossRef Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S (2012) Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Investig New Drugs 30:758–764CrossRef
24.
Zurück zum Zitat Ng SL, Burns WI, Snyder RD, Newnham GM, McLachlan SA, Liew D, Dowling AJ (2012) A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels. Asia Pac J Clin Oncol 8:172–179CrossRefPubMed Ng SL, Burns WI, Snyder RD, Newnham GM, McLachlan SA, Liew D, Dowling AJ (2012) A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels. Asia Pac J Clin Oncol 8:172–179CrossRefPubMed
25.
Zurück zum Zitat Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G (2012) CEA and CA 19.9 as early predictors of progression on advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Investig 30:65–71CrossRef Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G (2012) CEA and CA 19.9 as early predictors of progression on advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Investig 30:65–71CrossRef
26.
Zurück zum Zitat Kim G, Jung EJ, Ryu CG, Hwang DY (2013) Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. Yonsei Med J 54:116–122CrossRefPubMed Kim G, Jung EJ, Ryu CG, Hwang DY (2013) Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer. Yonsei Med J 54:116–122CrossRefPubMed
27.
Zurück zum Zitat Huang SC, Lin JK, Lin TC, Chen WS, Yang SH, Wang HS, Lan YT, Lin CC, Jiang JK, Chang SC (2015) Concordance of carcinoembryonic antigen ratio and response evaluation criteria in solid tumors as prognostic surrogate indicators of metastatic colorectal cancer patients treated with chemotherapy. Ann Surg Oncol 22:2262–2268CrossRefPubMed Huang SC, Lin JK, Lin TC, Chen WS, Yang SH, Wang HS, Lan YT, Lin CC, Jiang JK, Chang SC (2015) Concordance of carcinoembryonic antigen ratio and response evaluation criteria in solid tumors as prognostic surrogate indicators of metastatic colorectal cancer patients treated with chemotherapy. Ann Surg Oncol 22:2262–2268CrossRefPubMed
28.
Zurück zum Zitat Stremitzer S, Stift J, Graf A, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T (2015) CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases. Ann Surg Oncol 22:1315–1323CrossRefPubMed Stremitzer S, Stift J, Graf A, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T (2015) CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases. Ann Surg Oncol 22:1315–1323CrossRefPubMed
29.
Zurück zum Zitat Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V (2016) CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann Oncol 27:1565–1572CrossRefPubMed Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V (2016) CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann Oncol 27:1565–1572CrossRefPubMed
30.
Zurück zum Zitat Thyrunavukarasu P, Talati C, Munjal S, Attwood K, Edge SB, Francescutti V (2015) Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. JAMA Surg 150:747–755CrossRef Thyrunavukarasu P, Talati C, Munjal S, Attwood K, Edge SB, Francescutti V (2015) Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. JAMA Surg 150:747–755CrossRef
31.
Zurück zum Zitat Matias M, Casa-Nova M, Faria M, Pires R, Tato-Costa J, Ribeiro L, Costa L (2015) Prognostic factors after liver resection for colorectal liver metastasis. Acta Medica Port 28:357–369CrossRef Matias M, Casa-Nova M, Faria M, Pires R, Tato-Costa J, Ribeiro L, Costa L (2015) Prognostic factors after liver resection for colorectal liver metastasis. Acta Medica Port 28:357–369CrossRef
32.
Zurück zum Zitat Zhang ZY, Gao W, Luo QF, Yin XW, Basnet S, Dai ZL, Ge HY (2016) A nomogram improves AJCC stages for colorectal cancers by introducing CEA, modified lymph node ratio and negative lymph node count. Sci Rep 6:39028CrossRefPubMedPubMedCentral Zhang ZY, Gao W, Luo QF, Yin XW, Basnet S, Dai ZL, Ge HY (2016) A nomogram improves AJCC stages for colorectal cancers by introducing CEA, modified lymph node ratio and negative lymph node count. Sci Rep 6:39028CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Kirat HT, Ozturk E, Lavery IC, Kiran RP (2012) The predictive value of preoperative carcinoembryonic antigen level in the prognosis of colon cancer. Am J Surg 204:447–452CrossRefPubMed Kirat HT, Ozturk E, Lavery IC, Kiran RP (2012) The predictive value of preoperative carcinoembryonic antigen level in the prognosis of colon cancer. Am J Surg 204:447–452CrossRefPubMed
34.
Zurück zum Zitat Huh JW, Oh BR, Kim HR, Kim YJ (2010) Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol 101:396–400PubMed Huh JW, Oh BR, Kim HR, Kim YJ (2010) Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol 101:396–400PubMed
35.
Zurück zum Zitat Amri R, Bordeianou LG, Sylla P, Berger DL (2013) Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. J Surg Oncol 108:14–18CrossRefPubMed Amri R, Bordeianou LG, Sylla P, Berger DL (2013) Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. J Surg Oncol 108:14–18CrossRefPubMed
36.
Zurück zum Zitat Lou Z, Meng RG, Zhang W, Yu ED, Fu CG (2013) Preoperative carcinoembryonic antibody is predictive of distant metastasis in pathologically T1 colorectal cancer after radical surgery. W J Gastroenterol 19:389–393CrossRef Lou Z, Meng RG, Zhang W, Yu ED, Fu CG (2013) Preoperative carcinoembryonic antibody is predictive of distant metastasis in pathologically T1 colorectal cancer after radical surgery. W J Gastroenterol 19:389–393CrossRef
37.
Zurück zum Zitat Selculbiricik F, Bilici A, Tural D, Erdamar S, Ozlem S, Buyukunal E, Demirelli F, Serdengecti S (2013) Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumour Biol 34:2233–2239CrossRef Selculbiricik F, Bilici A, Tural D, Erdamar S, Ozlem S, Buyukunal E, Demirelli F, Serdengecti S (2013) Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumour Biol 34:2233–2239CrossRef
38.
Zurück zum Zitat Tampellini M, Ottone A, Alabiso I, Barattelli C, Forti L, Berruti A, Aroasio E, Scagliotti GV (2015) The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumor Biol 36:1519–1527CrossRef Tampellini M, Ottone A, Alabiso I, Barattelli C, Forti L, Berruti A, Aroasio E, Scagliotti GV (2015) The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumor Biol 36:1519–1527CrossRef
39.
Zurück zum Zitat Strimpakos AS, Cunningham D, Mikropoulos PI, Barbachano Y, Chau I (2010) The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol 21:1013–1019CrossRefPubMed Strimpakos AS, Cunningham D, Mikropoulos PI, Barbachano Y, Chau I (2010) The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol 21:1013–1019CrossRefPubMed
40.
Zurück zum Zitat Garcia M, Seigner C, Bastid C, Choux R, Payan MJ, Reggio H (1991) Carcinoembryonic antigen has a different molecular weight in normal colon and in cancer cells due to N-glycosilation differences. Cancer Res 51:5679–5686PubMed Garcia M, Seigner C, Bastid C, Choux R, Payan MJ, Reggio H (1991) Carcinoembryonic antigen has a different molecular weight in normal colon and in cancer cells due to N-glycosilation differences. Cancer Res 51:5679–5686PubMed
41.
Zurück zum Zitat Rao US, Hoerster NS, Thirumala S, Rao PS (2013) The influence of metastatic site on the expression of CEA and cellular localization of β-catenin in colorectal cancer. J Gastroenterol Hepatol 28:505–512CrossRefPubMed Rao US, Hoerster NS, Thirumala S, Rao PS (2013) The influence of metastatic site on the expression of CEA and cellular localization of β-catenin in colorectal cancer. J Gastroenterol Hepatol 28:505–512CrossRefPubMed
42.
Zurück zum Zitat Cho M, Akiba C, Lau C, Smith D, Telatar M, Afkhami M, Sentovich S, Melstrom K, Fakih M (2016) Impact of RAS e BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. World J Gastrointest Oncol 8:128–135CrossRefPubMedPubMedCentral Cho M, Akiba C, Lau C, Smith D, Telatar M, Afkhami M, Sentovich S, Melstrom K, Fakih M (2016) Impact of RAS e BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. World J Gastrointest Oncol 8:128–135CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS (2015) Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biol Ther 16:709–713CrossRefPubMedPubMedCentral Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS (2015) Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biol Ther 16:709–713CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Bystrom P, Berglund A, Nygren P, Wernroth L, Johansson B, Larsson A, Glimelius B (2012) Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol 51:849–859CrossRefPubMed Bystrom P, Berglund A, Nygren P, Wernroth L, Johansson B, Larsson A, Glimelius B (2012) Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol 51:849–859CrossRefPubMed
45.
Zurück zum Zitat Shinkins B, Nicholson BD, James TJ, Primrose JN, Mant D (2014) Carcinoembryonic antigen monitoring to detect recurrence of colorectal cancer: how should we interpret the test results? Clin Chem 60:1572–1574CrossRefPubMed Shinkins B, Nicholson BD, James TJ, Primrose JN, Mant D (2014) Carcinoembryonic antigen monitoring to detect recurrence of colorectal cancer: how should we interpret the test results? Clin Chem 60:1572–1574CrossRefPubMed
46.
Zurück zum Zitat Lee JH, Kim SH, Jang HS, Chung HJ, Oh ST, Lee DS, Kim JG (2013) Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. Int J Color Dis 28:511–517CrossRef Lee JH, Kim SH, Jang HS, Chung HJ, Oh ST, Lee DS, Kim JG (2013) Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. Int J Color Dis 28:511–517CrossRef
47.
Zurück zum Zitat Bajenova O, Gorbunova A, Evsyukov I, Rayko M, Gapon S, Bozhokina E, Shishkin A, O’Brien SJ (2016) The genome-wide analysis of carcinoembryonic antigen signaling by colorectal cancer cells using RNA sequencing. PLoS One 11:e0161256CrossRefPubMedPubMedCentral Bajenova O, Gorbunova A, Evsyukov I, Rayko M, Gapon S, Bozhokina E, Shishkin A, O’Brien SJ (2016) The genome-wide analysis of carcinoembryonic antigen signaling by colorectal cancer cells using RNA sequencing. PLoS One 11:e0161256CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Chiaravalloti A, Fiorentini A, Palombo E, Rinino D, Lacanfora A, Danieli R, Di Russo C, Di Biagio D, Squillaci E, Schillaci O (2016) Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F-FDG PET/TC: use of CEA and CA 19-9 in patient selection. Oncol Lett 12:4209–4213CrossRefPubMedPubMedCentral Chiaravalloti A, Fiorentini A, Palombo E, Rinino D, Lacanfora A, Danieli R, Di Russo C, Di Biagio D, Squillaci E, Schillaci O (2016) Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F-FDG PET/TC: use of CEA and CA 19-9 in patient selection. Oncol Lett 12:4209–4213CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Gade M, Kubik M, Fisker RV, Thorlacius-Ussing O, Petersen LJ (2015) Diagnostic value of 18F-FDG-PET/TC as first choice in the detection of recurrent colorectal cancer due to rising CEA. Cancer Imaging 15:11CrossRefPubMedPubMedCentral Gade M, Kubik M, Fisker RV, Thorlacius-Ussing O, Petersen LJ (2015) Diagnostic value of 18F-FDG-PET/TC as first choice in the detection of recurrent colorectal cancer due to rising CEA. Cancer Imaging 15:11CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Zhang Y, Feng B, Zhang GL, Hu M, Fu Z, Zhao F, Zhang XL, Kong L, Yu JM (2014) Value of 18F-FDG PET-TC in surveillance of post-operative colorectal cancer patients with various carcinoembryonic antigen concentrations. World J Gastoenterol 20:6608–6614CrossRef Zhang Y, Feng B, Zhang GL, Hu M, Fu Z, Zhao F, Zhang XL, Kong L, Yu JM (2014) Value of 18F-FDG PET-TC in surveillance of post-operative colorectal cancer patients with various carcinoembryonic antigen concentrations. World J Gastoenterol 20:6608–6614CrossRef
51.
Zurück zum Zitat Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, Zielinski CC, Prager GW (2013) Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res 73:6584–6596CrossRefPubMed Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, Zielinski CC, Prager GW (2013) Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res 73:6584–6596CrossRefPubMed
52.
Zurück zum Zitat Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MMY, Stanners CP (2007) GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin α5β1-fibronectin interaction. J Cell Physiol 210:757–765CrossRefPubMed Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MMY, Stanners CP (2007) GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin α5β1-fibronectin interaction. J Cell Physiol 210:757–765CrossRefPubMed
53.
Zurück zum Zitat Chan CHF, Camacho-Leal P, Stanners CP (2007) Colorectal hyperplasia and dysplasia due to human carcinoembryonic antigen (CEA) family member expression in transgenic mice. PLoS One 12:e1353CrossRef Chan CHF, Camacho-Leal P, Stanners CP (2007) Colorectal hyperplasia and dysplasia due to human carcinoembryonic antigen (CEA) family member expression in transgenic mice. PLoS One 12:e1353CrossRef
54.
Zurück zum Zitat Samara RN, Laguinge LM, Jessup JM (2007) Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with trail-R2 (DR5) signaling. Cancer Res 67:4774–4782CrossRefPubMed Samara RN, Laguinge LM, Jessup JM (2007) Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with trail-R2 (DR5) signaling. Cancer Res 67:4774–4782CrossRefPubMed
55.
Zurück zum Zitat Blumenthal RD, Hansen HJ, Goldenberg DM (2005) Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res 65:8809–8817CrossRefPubMed Blumenthal RD, Hansen HJ, Goldenberg DM (2005) Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res 65:8809–8817CrossRefPubMed
56.
Zurück zum Zitat Gemei M, Mirabelli P, Di Noto R, Corbo C, Iaccarino A, Zamboli A, Troncone G, Galizia G, Lieto E, Del Vecchio L, Salvatore F (2013) CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer 119:729–738CrossRefPubMed Gemei M, Mirabelli P, Di Noto R, Corbo C, Iaccarino A, Zamboli A, Troncone G, Galizia G, Lieto E, Del Vecchio L, Salvatore F (2013) CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer 119:729–738CrossRefPubMed
57.
Zurück zum Zitat Scurr MJ, Brown CM, Costa Bento DF, Betts GJ, Rees BI, Hills RK, Gallimore A, Godkin A (2015) Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. J Natl Cancer Inst 107:djv001CrossRefPubMedPubMedCentral Scurr MJ, Brown CM, Costa Bento DF, Betts GJ, Rees BI, Hills RK, Gallimore A, Godkin A (2015) Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. J Natl Cancer Inst 107:djv001CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat An X, Ding PR, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH, Li YH (2010) Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers 15:243–248CrossRefPubMed An X, Ding PR, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH, Li YH (2010) Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers 15:243–248CrossRefPubMed
59.
Zurück zum Zitat Aquino A, Formica V, Prete SP, Correale PP, Massara MC, Turriziani M, De Vecchis L, Bonmassar E (2004) Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 49:383–396CrossRefPubMed Aquino A, Formica V, Prete SP, Correale PP, Massara MC, Turriziani M, De Vecchis L, Bonmassar E (2004) Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 49:383–396CrossRefPubMed
60.
Zurück zum Zitat Eftekhar E, Naghibalhossaini F (2014) Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer. Mol Biol Rep 41:459–466CrossRefPubMed Eftekhar E, Naghibalhossaini F (2014) Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer. Mol Biol Rep 41:459–466CrossRefPubMed
61.
Zurück zum Zitat Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski C (2014) Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci 105:996–1001CrossRefPubMedPubMedCentral Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski C (2014) Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci 105:996–1001CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Yoshino T, Obermannovà R, Bodoky G, Garcia-Carbnero R, Ciuleanu T, Portnoy DC, Kim TW, Hsu Y, Ferry D, Nasroulah F, Taberbero J (2017) Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. Eur J Cancer 78:61–69CrossRefPubMed Yoshino T, Obermannovà R, Bodoky G, Garcia-Carbnero R, Ciuleanu T, Portnoy DC, Kim TW, Hsu Y, Ferry D, Nasroulah F, Taberbero J (2017) Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. Eur J Cancer 78:61–69CrossRefPubMed
63.
Zurück zum Zitat Seyal AR, Parekh K, Arslanoglu A, Gonzalez-Guindalini FD, Tochetto SM, Velichko YS, Yaghmai V (2015) Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET. Abdom Imaging 40:3043–3051CrossRefPubMed Seyal AR, Parekh K, Arslanoglu A, Gonzalez-Guindalini FD, Tochetto SM, Velichko YS, Yaghmai V (2015) Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET. Abdom Imaging 40:3043–3051CrossRefPubMed
64.
Zurück zum Zitat Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DP, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572CrossRefPubMedPubMedCentral Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DP, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Iwanicki-Caron I, Di Fiore F, Roque I, Astruc E, Stetiu M, Duclos A, Tougeron D, Saillard S, Thureau S, Benichou J, Paillot B, Basuyau JP, Michel P (2008) Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 26:3681–3686CrossRefPubMed Iwanicki-Caron I, Di Fiore F, Roque I, Astruc E, Stetiu M, Duclos A, Tougeron D, Saillard S, Thureau S, Benichou J, Paillot B, Basuyau JP, Michel P (2008) Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 26:3681–3686CrossRefPubMed
Metadaten
Titel
Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis
verfasst von
Giuseppe Antonio Colloca
Antonella Venturino
Domenico Guarneri
Publikationsdatum
22.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 4/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-018-03230-w

Weitere Artikel der Ausgabe 4/2019

International Journal of Colorectal Disease 4/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.